Device type · GKP
Instrument, Coagulation, Automated
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
GKP
Hematology
Device class
Class II
FDA decisions since 2015
4
510(k), De Novo and PMA
Adverse event reports
3
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Instrument, Coagulation, Automated
- Product code
- GKP
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.5400
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for GKP
Latest FDA decisions
Instrumentation Laboratory (IL) Co.
K242127 · Decided Aug 16, 2024 · 28 days after receipt
Device type: Instrument, Coagulation, Automated (GKP) · Laboratory Medicine & Pathology
- ACL TOP Family 70 Series510(k)
Instrumentation Laboratory Company
K231031 · Decided Jun 21, 2023 · 71 days after receipt
Device type: Instrument, Coagulation, Automated (GKP) · Laboratory Medicine & Pathology
K160276 · Decided Mar 3, 2016 · 30 days after receipt
Device type: Instrument, Coagulation, Automated (GKP) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Reports received
3
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
3
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 1 | 3 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 2 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results1
- Mechanical Problem1
- Patient Data Problem1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions3
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2578-2023 · Started Jul 13, 2023 · Posted by FDA Sep 12, 2023
Reason given: Sample misidentification could occur under specific conditions and patient management altered based on an incorrectly assigned result
Cause as FDA categorized it: Under Investigation by firm
Z-1014-2022 · Started Feb 22, 2022 · Posted by FDA Apr 28, 2022
Reason given: Updated and revised user instructions issued 7/14/22. Potential carryover issue may cause elevated quality control and sample results for heparin, apixaban or rivaroxaban when HemosIL Liquid Anti-Xa reagent is used in the same run with both HemosIL Liquid Antithrombin and HemosIL Q.F.A. Thrombin (Bovine), specific to...
Cause as FDA categorized it: Under Investigation by firm
Instrumentation Laboratory Co.
Z-2060-2014 · Started Jun 3, 2014 · Posted by FDA Jul 16, 2014
Reason given: Potential for sample misidentification.
Cause as FDA categorized it: Device Design
28 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.